Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase III Menveo Beats Menactra In Teen Meningitis

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis will submit vaccine for U.S. and overseas approval later this year.

You may also be interested in...



Novartis Vaccines Unit Makes Move Into Crowded CMV Competition

Licensing deal for AlphaVax’s Phase I CMV candidate also includes options for RSV vaccine candidate and 4 million share stock purchase.

Novartis Vaccines Unit Makes Move Into Crowded CMV Competition

Licensing deal for AlphaVax’s Phase I CMV candidate also includes options for RSV vaccine candidate and 4 million share stock purchase.

Novartis Meningitis Blockbuster Strategy Key To Firm’s Vaccine Growth

Novartis plans to submit ACWY meningitis BLA in the second half, putting Menveo on track for approval in 2009.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel